Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit due to alleged securities fraud related to the poor launch of its new product, Inspire V, which was marked by significant operational failures and misrepresentations to investors [3]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors affected by alleged securities fraud between August 6, 2024, and August 4, 2025 [2]. - Defendants are accused of making false statements and concealing the poor demand for Inspire V, as providers had excess inventory and were hesitant to adopt the new treatment [3]. - Key operational failures included incomplete training for treatment center customers, lack of necessary IT systems, and failure to secure Medicare reimbursement prior to the product launch [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until January 5, 2026, to request appointment as lead plaintiff, although participation does not require this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [5]. - The firm is recognized as one of the top securities litigation firms in the United States, with extensive expertise in complex cases [5].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, while in reality, the company failed to prepare clinicians and payors adequately, leading to significant delays in adoption [5][6]. - The launch of Inspire V faced weak demand as many customers had excess inventory of older devices, which contributed to the poor market reception [6]. Stock Performance - On August 4, 2025, Inspire disclosed that the launch of Inspire V would take longer than expected, resulting in a reduction of its 2025 earnings per share guidance by over 80% [7]. - Following this announcement, Inspire's stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Inspire Medical Systems, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [2][4]. Group 1: Class Action Details - Investors who bought Inspire Medical common stock between August 6, 2024, and August 4, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 5, 2026 [4][6]. - The lawsuit alleges that Inspire Medical misrepresented key facts about its sleep apnea device, Inspire V, including market demand and necessary steps for its launch, leading to investor damages when the truth was revealed [6]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [5]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been consistently ranked among the top firms for securities class action settlements since 2013 [5].

NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Inspire Medical Systems, Inc. (NYSE: INSP) between August 6, 2024 and August 4, 2025, both dates inclusive (the “Class Period”), of the important January 5, 2026 lead plaintiff deadline. SO WHAT: If you purchased Inspire Medical common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingenc ...

SAN FRANCISCO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Medical device manufacturer Inspire Medical Systems, Inc. (NYSE: INSP) is the subject of a securities class action lawsuit following a sharp decline in its stock price, with shareholders alleging the company misled investors about the launch of its latest product, the Inspire V device for obstructive sleep apnea. Hagens Berman is investigating the allegations. The firm urges investors in Inspire who suffered significant losses to submit your losses now. Class ...

Core Viewpoint - The company that manufactures an implant for treating sleep apnea has received an upgrade from Hold to Buy by Stifel [1] Company Summary - The implant is specifically designed for the treatment of sleep apnea, indicating a focus on addressing a significant health issue [1] Industry Summary - The upgrade reflects a positive outlook on the company's potential within the sleep apnea treatment market, suggesting increased investor confidence [1]

NEW YORK, Nov. 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Inspire Medical Systems, Inc. (NYSE: INSP). Accessibility StatementSkip Navigation Shareholders who purchased shares of INSP during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/inspire-medical-systems-inc-loss-su ...

Core Viewpoint - Inspire Medical Systems, Inc. is recognized for its innovative sleep apnea treatment solutions, particularly the Inspire therapy device, while facing a class action lawsuit that may impact investor sentiment [1][2][5] Company Overview - Inspire Medical Systems specializes in medical solutions for sleep apnea, particularly through its implantable Inspire therapy device [1] - The company's current stock price is $89.87, reflecting a recent increase of 7.92% or $6.60 [3][5] - The market capitalization of Inspire Medical Systems is approximately $2.66 billion, indicating its significant presence in the market [3] Analyst Ratings - Stifel Nicolaus has upgraded Inspire Medical Systems to a "Buy" rating with a price target of $110, suggesting a potential increase of 22.4% from the current stock price [1][5] Legal Challenges - The company is currently involved in a class action lawsuit led by the Schall Law Firm, alleging violations of the Securities Exchange Act of 1934, affecting investors who purchased INSP securities between August 6, 2024, and August 4, 2025 [2][5] - Shareholders who have experienced losses are encouraged to contact the law firm before January 5, 2026 [2] Trading Activity - The trading volume for INSP on the NYSE is 1,073,158 shares, indicating active investor interest despite ongoing legal challenges [4][5] - The stock has fluctuated between $83.37 and $90.55 today, with a yearly high of $216.01 and a low of $70.77 [3]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Chijet Motor Company, Inc. (CJET) is up 40% at $2.67 - JX Luxventure Group Inc. (JXG) is up 19% at $4.12 - Inspire Medical Systems, Inc. (INSP) is up 15% at $103.50 - Epsium Enterprise Limited (EPSM) is up 15% at $4.14 - Oscar Health, Inc. (OSCR) is up 12% at $15.13 - Green Dot Corporation (GDOT) is up 11% at $13.21 - Butterfly Network, Inc. (BFLY) is up 6% at $2.82 - Cullinan Therapeutics, Inc. (CGEM) is up 5% at $10.00 - Vir Biotechnology, Inc. (VIR) is up 5% at $5.99 - Nvni Group Limited (NVNI) is up 5% at $3.17 [3] Premarket Losers - Clearside Biomedical, Inc. (CLSD) is down 69% at $0.82 - Twin Hospitality Group Inc. (TWNP) is down 20% at $2.84 - Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is down 15% at $1.35 - Mobile-Network Solutions (MNDR) is down 12% at $4.16 - Waldencast plc (WALD) is down 10% at $2.75 - authID Inc. (AUID) is down 9% at $1.21 - EZGO Technologies Ltd. (EZGO) is down 6% at $1.98 - SciSparc Ltd. (SPRC) is down 5% at $2.34 - Twin Vee Powercats Co. (VEEE) is down 5% at $1.70 - Agape ATP Corporation (ATPC) is down 5% at $1.22 [4]

INSPIRE NOTICE: Inspire Medical Systems, Inc. (INSP) Faces Securities Fraud Allegations after Stock Drops 32%, Investors Urged to Contact BFA LawNovember 24, 2025 6:08 AM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 24, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company's senior executives for securities fraud after ...